SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, a leader in molecular diagnostics panel testing, is excited to announce a significant enhancement to its BioCode ® Gastrointestinal Pathogen ...
BEVERLY, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. (LXXGF), (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative ...
Background. Molecular syndromic diagnostic panels can enhance pathogen identification in the approximately 2–4 billion episodes of acute gastroenteritis that occur annually worldwide. However, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback